US · Healthcare · Diagnostics & Research
EPS came in at -0.10 against a street estimate of -0.13 — a beat of 23.1%.
Analysts rate Adaptive Biotechnologies Corp a buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $24.00.
| Fund | Stake |
|---|---|
| Viking Global Investors LP | 4.71% |
| BlackRock Inc | 2.09% |
| Vanguard Capital Management, LLC | 0.96% |
| Westfield Capital Management Company, L.P. | 0.85% |
| Vanguard Portfolio Management, LLC | 0.71% |
| Amvescap Plc. | 0.70% |
| Wellington Management Company LLP | 0.61% |
| Geode Capital Management, LLC | 0.57% |
| Document | Date |
|---|---|
| Results announced · Q3 2026 | 2026-07-29 |
| Material agreement · Q2 2026 | 2026-06-22 |
| Company announcement · Q2 2026 | 2026-06-15 |
| Shareholder vote results · Q2 2026 | 2026-06-09 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Adaptive Biotechnologies Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.